# BioSpring to build three oligonucleotide API production units in Offenbach, Germany

BioSpring acquired 30,000 sq m of land in Offenbach, Germany to build three new production units for oligonucleotide-based active pharmaceutical ingredients. The company plans to invest over €100 million and create 1,500 jobs.

- Type: New facility
- Announced: 2022-12-21
- Where: Offenbach, Germany, Germany
- Value: $106.0M (100.0M EUR)
- Jobs: 1,500
- Status: announced
- Products: oligonucleotide-based active pharmaceutical ingredients
- Sectors: [Specialty Chemicals](https://endata.com/sectors/specialty-chemicals.md)

## Companies

- [BioSpring](https://endata.com/companies/67473.md)

## Sources

- [endpoints.news](https://endpoints.news/biospring-invests-e100m-into-new-oligonucleotide-based-api-facilities-in-germany/), 2022-12-21: "BioSpring plans to invest upwards of €100 million ($106 million) and create 1,500 jobs in the long run."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.